drugmaker

US FDA qualifies first AI tool to help speed liver disease drug development

Drug developers are increasingly adopting artificial intelligence technologies

The tussle for Metsera began with discussions between the company and potential acquirers in early 2024, with both Pfizer and Novo Nordisk, the maker of Wegovy and Ozempic, expressing interest.

Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid

[BENGALURU] Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid ...

Pfizer’s top-selling drugs include the blood-thinner Eliquis, the pneumonia vaccine Prevnar, and a shot and pill for Covid-19.

Pfizer’s drug price cuts yield three-year Trump tariff reprieve

The US president has repeatedly pressured companies to bring their US prices in line with what foreign countries pay

Moderna shares dropped 7.4% in New York Friday. Pfizer shares fell 4%, while BioNTech’s US-traded shares sank 7.3%.

Drugmakers fall on report US to claim Covid shot killed kids

[WASHINGTON] Vaccine makers’ shares fell after a report that US President Donald Trump health officials plan to link Covid shots to the deaths of around two dozen children in a presentation to adviser...

Merck plans to reduce its global real estate footprint and optimise its manufacturing network.

Merck to cut jobs and costs as demand for Gardasil in China remains weak

The cost cuts include US$1.7 billion in annual savings from the elimination of certain administrative, sales and R&D positions

The government’s ‘Made in China 2025’ plan to elevate manufacturing in 10 priority sectors also helped spur a flurry of investments in biotechnology.

China biotech’s stunning advance is changing the world’s drug pipeline

Chinese’s biotech advances, the scale of which is slowly coming into view, risk becoming another realm of superpower rivalry such as artificial intelligence and electric vehicles

Sanofi plans to invest at least US$20 billion in the US through 2030 to boost manufacturing and research.

Sanofi to buy US biopharma group Blueprint for up to US$9.5 billion

The acquisition represents a strategic step forward in the French drugmaker’s rare and immunology portfolios

WeightWatchers says the restructuring plan will “significantly reduce” its debt obligations.

WeightWatchers files bankruptcy as GLP-1 drugs reshape market

Prepackaged bankruptcies generally allow companies to exit Chapter 11 quickly and without disruption to their business or unsecured creditors

China’s retaliatory tariff against US imports is already taking a toll on hospitals and drugmakers.

China asks drugmakers, hospitals to find US import substitutes

The tit-for-tat escalation has seen both sides ratchet up tariffs on each other’s goods to over 100 per cent, threatening to wipe out commerce between the world’s two largest economies